Krystal JH, Abdallah CG, Sanacora G, Charney DS, Duman RS: Ketamine: A Paradigm Shift for Depression Research and Treatment. Neuron. 2019 Mar 6. PMID: 30844397

Sanacora G: Caution Against Overinterpreting Opiate Receptor Stimulation as Mediating Antidepressant Effects of Ketamine. Am J Psychiatry. 2019 Mar 1. PMID: 30818992

Salloum NC, Fava M, Freeman MP, Flynn M, Hoeppner B, Hock RS, Cusin C, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Papakostas GI: Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depress Anxiety. 2019 Mar; 2018 Dec 30. PMID: 30597688

Freeman MP, Papakostas GI, Hoeppner B, Mazzone E, Judge H, Cusin C, Mathew S, Sanacora G, Iosifescu D, DeBattista C, Trivedi MH, Fava M: Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. J Psychiatr Res. 2019 Mar; 2019 Jan 8. PMID: 30641350

Mathew SJ, Wilkinson ST, Altinay M, Asghar-Ali A, Chang LC, Collins KA, Dale RM, Hu B, Krishnan K, Kellner CH, Malone DA, Murrough JW, Ostroff RB, Sanacora G, Shao M, Anand A: ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol. Contemp Clin Trials. 2019 Feb; 2018 Dec 17. PMID: 30572160

Wilkinson ST, Sanacora G: A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems. Drug Discov Today. 2019 Feb; 2018 Nov 14. PMID: 30447328

Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI: Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2019 Jan 7; 2019 Jan 7. PMID: 30617276

Krystal AD, Pizzagalli DA, Mathew SJ, Sanacora G, Keefe R, Song A, Calabrese J, Goddard A, Goodman W, Lisanby SH, Smoski M, Weiner R, Iosifescu D, Nurnberger J Jr, Szabo S, Murrough J, Shekhar A, Potter W: The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. Nat Rev Drug Discov. 2018 Dec 28. PMID: 30591715

Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2018 Oct 3; 2018 Oct 3. PMID: 30283029

Abdallah CG, Sanacora G, Duman RS, Krystal JH: The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation? Pharmacol Ther. 2018 Oct; 2018 May 25. PMID: 29803629

Abdallah CG, De Feyter HM, Averill LA, Jiang L, Averill CL, Chowdhury GMI, Purohit P, de Graaf RA, Esterlis I, Juchem C, Pittman BP, Krystal JH, Rothman DL, Sanacora G, Mason GF: The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. Neuropsychopharmacology. 2018 Sep; 2018 Jun 28. PMID: 29977074

Wilkinson ST, Katz RB, Toprak M, Webler R, Ostroff RB, Sanacora G: Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital. J Clin Psychiatry. 2018 Jul 24; 2018 Jul 24. PMID: 30063304

Canuso CM, Singh JB, Fedgchin M, Alphs L, Lane R, Lim P, Pinter C, Hough D, Sanacora G, Manji H, Drevets WC: Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. Am J Psychiatry. 2018 Jul 1; 2018 Apr 16. PMID: 29656663

Sanacora G: Hopes and Skepticism for Unraveling the Unique Mechanisms of Ketamine's Rapid Onset Antidepressant Actions in Rodent Models. Biol Psychiatry. 2018 Jul 1. PMID: 29929579

Esterlis I, DellaGioia N, Pietrzak RH, Matuskey D, Nabulsi N, Abdallah CG, Yang J, Pittenger C, Sanacora G, Krystal JH, Parsey RV, Carson RE, DeLorenzo C: Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression. Mol Psychiatry. 2018 Apr; 2017 Apr 11. PMID: 28397841

Wilkinson ST, Sanacora G: Authorship Credit for Large Clinical Trials. JAMA. 2018 Feb 20. PMID: 29466586

Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, Sos P, Wang G, Zarate CA Jr, Sanacora G: The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. Am J Psychiatry. 2018 Feb 1; 2017 Oct 3. PMID: 28969441

van Schalkwyk GI, Wilkinson ST, Davidson L, Silverman WK, Sanacora G: Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale. J Affect Disord. 2018 Feb; 2017 Sep 28. PMID: 29045915

Fava M, Freeman MP, Flynn M, Hoeppner BB, Shelton R, Iosifescu DV, Murrough JW, Mischoulon D, Cusin C, Rapaport M, Dunlop BW, Trivedi MH, Jha M, Sanacora G, Hermes G, Papakostas GI: Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). Brain Stimul. 2018 Jan - Feb; 2017 Sep 23. PMID: 29030111

Katz RB, Toprak M, Wilkinson ST, Sanacora G, Ostroff R: Concurrent use of ketamine and monoamine oxidase inhibitors in the treatment of depression: A letter to the editor. Gen Hosp Psychiatry. 2018 Sep - Oct; 2018 May 22. PMID: 30100209

Mathew SJ, Gueorguieva R, Brandt C, Fava M, Sanacora G: A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder. Neuropsychopharmacology. 2017 Dec; 2017 May 29. PMID: 28553836

Wilkinson ST, Sanacora G: Considerations on the Off-label Use of Ketamine as a Treatment for Mood Disorders. JAMA. 2017 Sep 5. PMID: 28806440

Medeiros da Frota Ribeiro C, Sanacora G, Ostroff R: Reply to: Ketamine and Psychosis History: Antidepressant Efficacy and Psychotomimetic Effects Postinfusion. Biol Psychiatry. 2017 Sep 1; 2017 Jan 23. PMID: 28262251

Klingensmith KE, Sanacora G, Ostroff R: Co-occurring Catatonia and Posterior Reversible Encephalopathy Syndrome Responsive to Electroconvulsive Therapy. J ECT. 2017 Sep. PMID: 28383349

Sanacora G: Ketamine for the Treatment of Depression-Reply. JAMA Psychiatry. 2017 Sep 1. PMID: 28700772

Krystal JH, Abdallah CG, Averill LA, Kelmendi B, Harpaz-Rotem I, Sanacora G, Southwick SM, Duman RS: Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic. Curr Psychiatry Rep. 2017 Aug 26; 2017 Aug 26. PMID: 28844076

Wilkinson ST, Toprak M, Turner MS, Levine SP, Katz RB, Sanacora G: A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders. Am J Psychiatry. 2017 Jul 1. PMID: 28669202

Abdallah CG, Hannestad J, Mason GF, Holmes SE, DellaGioia N, Sanacora G, Jiang L, Matuskey D, Satodiya R, Gasparini F, Lin X, Javitch J, Planeta B, Nabulsi N, Carson RE, Esterlis I: Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study. Biol Psychiatry Cogn Neurosci Neuroimaging. 2017 Jul; 2017 Apr 6. PMID: 28993818

Wilkinson ST, Sanacora G, Bloch MH: Hippocampal volume changes following electroconvulsive therapy: a systematic review and meta-analysis. Biol Psychiatry Cogn Neurosci Neuroimaging. 2017 May; 2017 Feb 5. PMID: 28989984

Sanacora G, Heimer H, Hartman D, Mathew SJ, Frye M, Nemeroff C, Robinson Beale R: Balancing the Promise and Risks of Ketamine Treatment for Mood Disorders. Neuropsychopharmacology. 2017 May; 2016 Sep 19. PMID: 27640324

Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, Summergrad P, Nemeroff CB, American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments.: A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry. 2017 Apr 1. PMID: 28249076

Wilkinson ST, Ostroff RB, Sanacora G: Computer-Assisted Cognitive Behavior Therapy to Prevent Relapse Following Electroconvulsive Therapy. J ECT. 2017 Mar. PMID: 27564424

Sanacora G, Johnson MR, Khan A, Atkinson SD, Riesenberg RR, Schronen JP, Burke MA, Zajecka JM, Barra L, Su HL, Posener JA, Bui KH, Quirk MC, Piser TM, Mathew SJ, Pathak S: Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study. Neuropsychopharmacology. 2017 Mar; 2016 Sep 29. PMID: 27681442

Banasr M, Lepack A, Fee C, Duric V, Maldonado-Aviles J, DiLeone R, Sibille E, Duman RS, Sanacora G: Characterization of GABAergic marker expression in the chronic unpredictable stress model of depression. Chronic Stress (Thousand Oaks). 2017 Feb; 2017 Aug 3. PMID: 28835932

Chowdhury GM, Zhang J, Thomas M, Banasr M, Ma X, Pittman B, Bristow L, Schaeffer E, Duman RS, Rothman DL, Behar KL, Sanacora G: Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects. Mol Psychiatry. 2017 Jan; 2016 Apr 12. PMID: 27067013

Haroon E, Miller AH, Sanacora G: Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders. Neuropsychopharmacology. 2017 Jan; 2016 Sep 15. PMID: 27629368

Wilkinson ST, Wright D, Fasula MK, Fenton L, Griepp M, Ostroff RB, Sanacora G: Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression. Psychother Psychosom. 2017; 2017 May 11. PMID: 28490030

Singh JB, Fedgchin M, Daly EJ, De Boer P, Cooper K, Lim P, Pinter C, Murrough JW, Sanacora G, Shelton RC, Kurian B, Winokur A, Fava M, Manji H, Drevets WC, Van Nueten L: A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. Am J Psychiatry. 2016 Aug 1; 2016 Apr 8. PMID: 27056608

Wilkinson ST, Sanacora G: KETAMINE: A POTENTIAL RAPID-ACTING ANTISUICIDAL AGENT? Depress Anxiety. 2016 Aug; 2016 Apr 15. PMID: 27082101

Abdallah CG, Adams TG, Kelmendi B, Esterlis I, Sanacora G, Krystal JH: KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS. Depress Anxiety. 2016 Aug; 2016 Apr 6. PMID: 27062302

Krystal JH, Abi-Dargham A, Akbarian S, Arnsten AFT, Barch DM, Bearden CE, Braff DL, Brown ES, Bullmore ET, Carlezon WA Jr, Carter CS, Cook EH Jr, Daskalakis ZJ, DiLeone RJ, Duman RS, Grace AA, Hariri AR, Harrison PJ, Hiroi N, Kenny PJ, Kleinman JE, Krystal AD, Lewis DA, Lipska BK, Marder SR, Mason GF, Mathalon DH, McClung CA, McDougle CJ, McIntosh AM, McMahon FJ, Mirnics K, Monteggia LM, Narendran R, Nestler EJ, Neumeister A, O'Donovan MC, Öngür D, Pariante CM, Paulus MP, Pearlson G, Phillips ML, Pine DS, Pizzagalli DA, Pletnikov MV, Ragland JD, Rapoport JL, Ressler KJ, Russo SJ, Sanacora G, Sawa A, Schatzberg AF, Shaham Y, Shamay-Tsoory SG, Sklar P, State MW, Stein MB, Strakowski SM, Taylor SF, Turecki G, Turetsky BI, Weissman MM, Zachariou V, Zarate CA Jr, Zubieta JK: Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research. Biol Psychiatry. 2016 Jul 15. PMID: 27346079

Sanacora G: What Are We Learning From Early-Phase Clinical Trials With Glutamate Targeting Medications for the Treatment of Major Depressive Disorder. JAMA Psychiatry. 2016 Jul 1. PMID: 27303925

Ribeiro CM, Sanacora G, Hoffman R, Ostroff R: The Use of Ketamine for the Treatment of Depression in the Context of Psychotic Symptoms: To the Editor. Biol Psychiatry. 2016 May 1; 2015 Jun 4. PMID: 26212896

Duman RS, Aghajanian GK, Sanacora G, Krystal JH: Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016 Mar. PMID: 26937618

Niciu MJ, Abdallah CG, Fenton LR, Fasula MK, Black A, Anderson GM, Sanacora G: A history of early life parental loss or separation is associated with successful cognitive-behavioral therapy in major depressive disorder. J Affect Disord. 2015 Nov 15; 2015 Aug 19. PMID: 26363143

Pittenger C, Bloch MH, Wasylink S, Billingslea E, Simpson R, Jakubovski E, Kelmendi B, Sanacora G, Coric V: Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial. J Clin Psychiatry. 2015 Aug. PMID: 26214725

Sanacora G, Schatzberg AF: Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology. 2015 Mar 13; 2015 Mar 13. PMID: 25767082

DeLorenzo C, DellaGioia N, Bloch M, Sanacora G, Nabulsi N, Abdallah C, Yang J, Wen R, Mann JJ, Krystal JH, Parsey RV, Carson RE, Esterlis I: In vivo ketamine-induced changes in [¹¹C]ABP688 binding to metabotropic glutamate receptor subtype 5. Biol Psychiatry. 2015 Feb 1; 2014 Jul 10. PMID: 25156701

Abdallah CG, Sanacora G, Duman RS, Krystal JH: Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu Rev Med. 2015; 2014 Oct 17. PMID: 25341010

McCullumsmith RE, Sanacora G: Regulation of extrasynaptic glutamate levels as a pathophysiological mechanism in disorders of motivation and addiction. Neuropsychopharmacology. 2015 Jan. PMID: 25482181

Sanacora G, Schatzberg AF: Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology. 2015 Jan; 2014 Sep 26. PMID: 25257213

Abdallah CG, Jiang L, De Feyter HM, Fasula M, Krystal JH, Rothman DL, Mason GF, Sanacora G: Glutamate metabolism in major depressive disorder. Am J Psychiatry. 2014 Dec 1; 2014 Oct 31. PMID: 25073688

Sanacora G, Smith MA, Pathak S, Su HL, Boeijinga PH, McCarthy DJ, Quirk MC: Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry. 2014 Sep; 2013 Oct 15. PMID: 24126931

Abdallah CG, Niciu MJ, Fenton LR, Fasula MK, Jiang L, Black A, Rothman DL, Mason GF, Sanacora G: Decreased occipital cortical glutamate levels in response to successful cognitive-behavioral therapy and pharmacotherapy for major depressive disorder. Psychother Psychosom. 2014; 2014 Aug 6. PMID: 25116726

Niciu MJ, Henter ID, Sanacora G, Zarate CA Jr: Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity? World J Biol Psychiatry. 2014 Jan; 2013 Sep 12. PMID: 24024876

Voleti B, Navarria A, Liu RJ, Banasr M, Li N, Terwilliger R, Sanacora G, Eid T, Aghajanian G, Duman RS: Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol Psychiatry. 2013 Nov 15; 2013 Jun 14. PMID: 23751205

Cardoos A, Inamori A, Sanacora G, Fava M, Mischoulon D: Delayed amnesic syndrome after riluzole use in major depressive disorder: a case report. Psychosomatics. 2013 Sep-Oct; 2013 Mar 6. PMID: 23473447

Sanacora G, Banasr M: From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders. Biol Psychiatry. 2013 Jun 15. PMID: 23726152

Krystal JH, Sanacora G, Duman RS: Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry. 2013 Jun 15. PMID: 23726151

Bloch MH, Wasylink S, Landeros-Weisenberger A, Panza KE, Billingslea E, Leckman JF, Krystal JH, Bhagwagar Z, Sanacora G, Pittenger C: Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol Psychiatry. 2012 Dec 1; 2012 Jul 10. PMID: 22784486

Laje G, Lally N, Mathews D, Brutsche N, Chemerinski A, Akula N, Kelmendi B, Simen A, McMahon FJ, Sanacora G, Zarate C Jr: Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol Psychiatry. 2012 Dec 1; 2012 Jul 6. PMID: 22771240

Abdallah CG, Fasula M, Kelmendi B, Sanacora G, Ostroff R: Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting. J ECT. 2012 Sep. PMID: 22847373

Chowdhury GM, Behar KL, Cho W, Thomas MA, Rothman DL, Sanacora G: ¹H-[¹³C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism. Biol Psychiatry. 2012 Jun 1; 2011 Dec 9. PMID: 22169441

Morgan PT, Pace-Schott EF, Mason GF, Forselius E, Fasula M, Valentine GW, Sanacora G: Cortical GABA levels in primary insomnia. Sleep. 2012 Jun 1; 2012 Jun 1. PMID: 22654200

McCarthy DJ, Alexander R, Smith MA, Pathak S, Kanes S, Lee CM, Sanacora G: Glutamate-based depression GBD. Med Hypotheses. 2012 May; 2012 Mar 4. PMID: 22391030

Gomez R, Behar KL, Watzl J, Weinzimer SA, Gulanski B, Sanacora G, Koretski J, Guidone E, Jiang L, Petrakis IL, Pittman B, Krystal JH, Mason GF: Intravenous ethanol infusion decreases human cortical γ-aminobutyric acid and N-acetylaspartate as measured with proton magnetic resonance spectroscopy at 4 tesla. Biol Psychiatry. 2012 Feb 1; 2011 Aug 19. PMID: 21855054

Siegel S, Sanacora G: The roles of glutamate receptors across major neurological and psychiatric disorders. Pharmacol Biochem Behav. 2012 Feb; 2011 Nov 13. PMID: 22108650

Niciu MJ, Kelmendi B, Sanacora G: Overview of glutamatergic neurotransmission in the nervous system. Pharmacol Biochem Behav. 2012 Feb; 2011 Aug 26. PMID: 21889952

Gourley SL, Espitia JW, Sanacora G, Taylor JR: Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice. Psychopharmacology (Berl). 2012 Feb; 2011 Jul 21. PMID: 21779782

Sanacora G, Treccani G, Popoli M: Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012 Jan; 2011 Aug 3. PMID: 21827775

Popoli M, Yan Z, McEwen BS, Sanacora G: The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci. 2011 Nov 30; 2011 Nov 30. PMID: 22127301

Kelmendi B, Holsbach-Beltrame M, McIntosh AM, Hilt L, George ED, Kitchen RR, Carlyle BC, Pittenger C, Coric V, Nolen-Hoeksema S, Sanacora G, Simen AA: Association of polymorphisms in HCN4 with mood disorders and obsessive compulsive disorder. Neurosci Lett. 2011 Jun 8; 2011 Apr 20. PMID: 21529705

Saricicek A, Maloney K, Muralidharan A, Ruf B, Blumberg HP, Sanacora G, Lorberg B, Pittman B, Bhagwagar Z: Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011 Jun; 2010 Oct 19. PMID: 21034692

Valentine GW, Mason GF, Gomez R, Fasula M, Watzl J, Pittman B, Krystal JH, Sanacora G: The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res. 2011 Feb 28; 2011 Jan 12. PMID: 21232924

Husky MM, Gindre C, Mazure CM, Brebant C, Nolen-Hoeksema S, Sanacora G, Swendsen J: Computerized ambulatory monitoring in mood disorders: feasibility, compliance, and reactivity. Psychiatry Res. 2010 Jul 30; 2010 May 21. PMID: 20488558

Banasr M, Chowdhury GM, Terwilliger R, Newton SS, Duman RS, Behar KL, Sanacora G: Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry. 2010 May; 2008 Sep 30. PMID: 18825147

Sanacora G: Cortical inhibition, gamma-aminobutyric acid, and major depression: there is plenty of smoke but is there fire? Biol Psychiatry. 2010 Mar 1. PMID: 20159143

Maciag D, Hughes J, O'Dwyer G, Pride Y, Stockmeier CA, Sanacora G, Rajkowska G: Reduced density of calbindin immunoreactive GABAergic neurons in the occipital cortex in major depression: relevance to neuroimaging studies. Biol Psychiatry. 2010 Mar 1; 2009 Dec 9. PMID: 20004363

Sanacora G: Do glutamatergic agents represent a new class of antidepressant drugs? Part 2. J Clin Psychiatry. 2009 Nov. PMID: 20031105

Sanacora G: Do glutamatergic agents represent a new class of antidepressant drugs? Part 1. J Clin Psychiatry. 2009 Oct. PMID: 19906350

Valentine GW, Sanacora G: Targeting glial physiology and glutamate cycling in the treatment of depression. Biochem Pharmacol. 2009 Sep 1; 2009 Apr 17. PMID: 19376090

Krystal JH, Tolin DF, Sanacora G, Castner SA, Williams GV, Aikins DE, Hoffman RE, D'Souza DC: Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. Drug Discov Today. 2009 Jul; 2009 May 19. PMID: 19460458

Sanacora G: Reviewing medications for bipolar disorder: understanding the mechanisms of action. J Clin Psychiatry. 2009 Jan. PMID: 19222977

Chowdhury GM, Banasr M, de Graaf RA, Rothman DL, Behar KL, Sanacora G: Chronic riluzole treatment increases glucose metabolism in rat prefrontal cortex and hippocampus. J Cereb Blood Flow Metab. 2008 Dec; 2008 Jul 16. PMID: 18628780

Sen S, Duman R, Sanacora G: Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry. 2008 Sep 15; 2008 Jun 24. PMID: 18571629

Sen S, Sanacora G: Major depression: emerging therapeutics. Mt Sinai J Med. 2008 May-Jun. PMID: 18704976

Sanacora G, Zarate CA, Krystal JH, Manji HK: Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov. 2008 May. PMID: 18425072

Krystal JH, Carter CS, Geschwind D, Manji HK, March JS, Nestler EJ, Zubieta JK, Charney DS, Goldman D, Gur RE, Lieberman JA, Roy-Byrne P, Rubinow DR, Anderson SA, Barondes S, Berman KF, Blair J, Braff DL, Brown ES, Calabrese JR, Carlezon WA Jr, Cook EH Jr, Davidson RJ, Davis M, Desimone R, Drevets WC, Duman RS, Essock SM, Faraone SV, Freedman R, Friston KJ, Gelernter J, Geller B, Gill M, Gould E, Grace AA, Grillon C, Gueorguieva R, Hariri AR, Innis RB, Jones EG, Kleinman JE, Koob GF, Krystal AD, Leibenluft E, Levinson DF, Levitt PR, Lewis DA, Liberzon I, Lipska BK, Marder SR, Markou A, Mason GF, McDougle CJ, McEwen BS, McMahon FJ, Meaney MJ, Meltzer HY, Merikangas KR, Meyer-Lindenberg A, Mirnics K, Monteggia LM, Neumeister A, O'Brien CP, Owen MJ, Pine DS, Rapoport JL, Rauch SL, Robbins TW, Rosenbaum JF, Rosenberg DR, Ross CA, Rush AJ, Sackeim HA, Sanacora G, Schatzberg AF, Shaham Y, Siever LJ, Sunderland T, Tecott LH, Thase ME, Todd RD, Weissman MM, Yehuda R, Yoshikawa T, Young EA, McCandless R: It is time to take a stand for medical research and against terrorism targeting medical scientists. Biol Psychiatry. 2008 Apr 15. PMID: 18371494

Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G: Riluzole in the treatment of mood and anxiety disorders. CNS Drugs. 2008. PMID: 18698875

Sanacora G: New understanding of mechanisms of action of bipolar medications. J Clin Psychiatry. 2008. PMID: 19265637

Sanacora G, Saricicek A: GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action. CNS Neurol Disord Drug Targets. 2007 Apr. PMID: 17430150

Pittenger C, Sanacora G, Krystal JH: The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Disord Drug Targets. 2007 Apr. PMID: 17430148

Sanacora G, Kendell SF, Levin Y, Simen AA, Fenton LR, Coric V, Krystal JH: Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry. 2007 Mar 15; 2006 Dec 4. PMID: 17141740

Mineur YS, Picciotto MR, Sanacora G: Antidepressant-like effects of ceftriaxone in male C57BL/6J mice. Biol Psychiatry. 2007 Jan 15; 2006 Jul 24. PMID: 16860779

Fenton L, Fasula M, Ostroff R, Sanacora G: Can cognitive behavioral therapy reduce relapse rates of depression after ECT? a preliminary study. J ECT. 2006 Sep. PMID: 16957536

Gueorguieva RV, Sanacora G: Joint analysis of repeatedly observed continuous and ordinal measures of disease severity. Stat Med. 2006 Apr 30. PMID: 16217846

Geracioti TD Jr, Carpenter LL, Owens MJ, Baker DG, Ekhator NN, Horn PS, Strawn JR, Sanacora G, Kinkead B, Price LH, Nemeroff CB: Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression. Am J Psychiatry. 2006 Apr. PMID: 16585438

Pittenger C, Naungayan C, Kendell SF, Coric V, Malison R, Krystal JH, Sanacora GS: Visual hallucinations from the addition of riluzole to memantine and bupropion. J Clin Psychopharmacol. 2006 Apr. PMID: 16633160

Sanacora G, Fenton LR, Fasula MK, Rothman DL, Levin Y, Krystal JH, Mason GF: Cortical gamma-aminobutyric acid concentrations in depressed patients receiving cognitive behavioral therapy. Biol Psychiatry. 2006 Feb 1; 2005 Sep 1. PMID: 16139814

Staley JK, Sanacora G, Tamagnan G, Maciejewski PK, Malison RT, Berman RM, Vythilingam M, Kugaya A, Baldwin RM, Seibyl JP, Charney D, Innis RB: Sex differences in diencephalon serotonin transporter availability in major depression. Biol Psychiatry. 2006 Jan 1; 2005 Sep 1. PMID: 16139815

Lafleur DL, Pittenger C, Kelmendi B, Gardner T, Wasylink S, Malison RT, Sanacora G, Krystal JH, Coric V: N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl). 2006 Jan; 2005 Dec 22. PMID: 16374600

Kugaya A, Sanacora G: Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr. 2005 Oct. PMID: 16400244

Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, Malison RT, Krystal JH: Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry. 2005 Sep 1. PMID: 15993857

Ostroff R, Gonzales M, Sanacora G: Antidepressant effect of ketamine during ECT. Am J Psychiatry. 2005 Jul. PMID: 15994728

Kendell SF, Krystal JH, Sanacora G: GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opin Ther Targets. 2005 Feb. PMID: 15757488

Epperson CN, O'Malley S, Czarkowski KA, Gueorguieva R, Jatlow P, Sanacora G, Rothman DL, Krystal JH, Mason GF: Sex, GABA, and nicotine: the impact of smoking on cortical GABA levels across the menstrual cycle as measured with proton magnetic resonance spectroscopy. Biol Psychiatry. 2005 Jan 1. PMID: 15607299

Sanacora G, Kendell SF, Fenton L, Coric V, Krystal JH: Riluzole augmentation for treatment-resistant depression. Am J Psychiatry. 2004 Nov. PMID: 15514421

Kugaya A, Sanacora G, Staley JK, Malison RT, Bozkurt A, Khan S, Anand A, Van Dyck CH, Baldwin RM, Seibyl JP, Charney D, Innis RB: Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biol Psychiatry. 2004 Oct 1. PMID: 15450785

Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL, Krystal JH, Mason GF: Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry. 2004 Jul. PMID: 15237082

Sanacora G, Berman RM, Cappiello A, Oren DA, Kugaya A, Liu N, Gueorguieva R, Fasula D, Charney DS: Addition of the alpha2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response. Neuropsychopharmacology. 2004 Jun. PMID: 15010697

Perry EB, Berman RM, Sanacora G, Anand A, Lynch-Colonese K, Charney DS: Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. J Clin Psychiatry. 2004 Feb. PMID: 15003079

Lappalainen J, Sanacora G, Kranzler HR, Malison R, Hibbard ES, Price LH, Krystal J, Gelernter J: Mutation screen of the glutamate decarboxylase-67 gene and haplotype association to unipolar depression. Am J Med Genet B Neuropsychiatr Genet. 2004 Jan 1. PMID: 14681921

Sanacora G, Rothman DL, Mason G, Krystal JH: Clinical studies implementing glutamate neurotransmission in mood disorders. Ann N Y Acad Sci. 2003 Nov. PMID: 14684453

Kugaya A, Sanacora G, Verhoeff NP, Fujita M, Mason GF, Seneca NM, Bozkurt A, Khan SA, Anand A, Degen K, Charney DS, Zoghbi SS, Baldwin RM, Seibyl JP, Innis RB: Cerebral benzodiazepine receptors in depressed patients measured with [123I]iomazenil SPECT. Biol Psychiatry. 2003 Oct 15. PMID: 14550678

Sanacora G, Mason GF, Rothman DL, Hyder F, Ciarcia JJ, Ostroff RB, Berman RM, Krystal JH: Increased cortical GABA concentrations in depressed patients receiving ECT. Am J Psychiatry. 2003 Mar. PMID: 12611844

Sanacora G, Mason GF, Rothman DL, Krystal JH: Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry. 2002 Apr. PMID: 11925309

Berman RM, Sanacora G, Anand A, Roach LM, Fasula MK, Finkelstein CO, Wachen RM, Oren DA, Heninger GR, Charney DS: Monoamine depletion in unmedicated depressed subjects. Biol Psychiatry. 2002 Mar 15. PMID: 11922881

Cubells JF, Price LH, Meyers BS, Anderson GM, Zabetian CP, Alexopoulos GS, Nelson JC, Sanacora G, Kirwin P, Carpenter L, Malison RT, Gelernter J: Genotype-controlled analysis of plasma dopamine beta-hydroxylase activity in psychotic unipolar major depression. Biol Psychiatry. 2002 Mar 1. PMID: 11904129

Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, Epperson CN, Goddard A, Mason GF: Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry. 2002. PMID: 11986998

Krystal JH, D'Souza DC, Sanacora G, Goddard AW, Charney DS: Current perspectives on the pathophysiology of schizophrenia, depression, and anxiety disorders. Med Clin North Am. 2001 May. PMID: 11349473

Chen AC, Shin KH, Duman RS, Sanacora G: ECS-Induced mossy fiber sprouting and BDNF expression are attenuated by ketamine pretreatment. J ECT. 2001 Mar. PMID: 11281511

Berman RM, Narasimhan M, Sanacora G, Miano AP, Hoffman RE, Hu XS, Charney DS, Boutros NN: A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression. Biol Psychiatry. 2000 Feb 15. PMID: 10686268

Sanacora G, Mason GF, Krystal JH: Impairment of GABAergic transmission in depression: new insights from neuroimaging studies. Crit Rev Neurobiol. 2000. PMID: 11253954

Sanacora G, Mason GF, Rothman DL, Behar KL, Hyder F, Petroff OA, Berman RM, Charney DS, Krystal JH: Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 1999 Nov. PMID: 10565505

Malison RT, Price LH, Berman R, van Dyck CH, Pelton GH, Carpenter L, Sanacora G, Owens MJ, Nemeroff CB, Rajeevan N, Baldwin RM, Seibyl JP, Innis RB, Charney DS: Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry. 1998 Dec 1. PMID: 9836013

Chang R, Sanacora G, Sanchez R Jr: The need for outcome studies. J Am Acad Child Adolesc Psychiatry. 1996 May. PMID: 8935198

Schwartz MW, Sipols AJ, Marks JL, Sanacora G, White JD, Scheurink A, Kahn SE, Baskin DG, Woods SC, Figlewicz DP: Inhibition of hypothalamic neuropeptide Y gene expression by insulin. Endocrinology. 1992 Jun. PMID: 1597158

Sanacora G, Finkelstein JA, Whitet JD: Developmental aspect of differences in hypothalamic preproneuropeptide y messenger ribonucleic Acid content in lean and genetically obese zucker rats. J Neuroendocrinol. 1992 Jun. PMID: 21554617


Yale Depression Research Program
100 York Street, Suite 2J
New Haven, CT 06511

T 203.764.9131

41.30699 -72.93328
View our current studies